Physician profile
Shannon E Vickers
NPI 1528494150
$4,255.20
in general payments reported to CMS, 2019-2025
31 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $756 · 2022: $921 · 2023: $500 · 2024: $780 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.64 |
| Education | $219.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $752.32 | 2021-2025 | Dupixent |
| Csl Behring | $485.62 | 2021-2025 | Hizentra, Andembry, Haegarda |
| Glaxosmithkline, LLC. | $316.39 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $291.11 | 2021-2025 | |
| Amgen INC. | $264.34 | 2021-2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $252.94 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Galderma Laboratories, L.P. | $223.22 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $178.52 | 2021-2025 | Takhzyro |
| Optinose US, INC. | $154.72 | 2022-2025 | |
| Kaleo, INC. | $130.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $126.95 | 2025 | |
| Covis Pharma Gmbh | $110.82 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $108.34 | 2021-2022 | |
| Blueprint Medicines Corporation | $97.73 | 2023-2025 | Ayvakit |
| Grifols USA, LLC | $92.61 | 2022-2024 | Xembify, Prolastin-C Liquid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $91.26 | 2021-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $78.57 | 2025 | Neffy |
| Abbvie INC. | $65.15 | 2022-2023 | |
| Alk-Abello, INC | $59.24 | 2021-2023 | Standardized Mite D. Farinae, Timothy, Standardized, Pre-Pen |
| Genentech USA, INC. | $52.82 | 2025 | Xolair |
| Pfizer INC. | $51.67 | 2021-2022 | |
| Pharming Healthcare, INC. | $44.81 | 2021-2025 | Ruconest |
| Verona Pharma, INC. | $40.85 | 2025 | Ohtuvayre |
| Octapharma USA, INC. | $34.76 | 2021-2024 | Cutaquig |
| Merck Sharp & Dohme LLC | $28.26 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $26.85 | 2023 | |
| Leo Pharma INC. | $22.06 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.02 | 2025 | Xhance, Nuzyra |
| Sanofi-Aventis U.S. LLC | $18.49 | 2021 | |
| Uswm, LLC | $17.00 | 2021 | |
| Hikma Pharmaceuticals USA | $14.92 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Vickers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.